TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of ...

NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...

scPharmaceuticals Inc. ( NASDAQ: SCPH) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior ...

Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results ...

A new way of treating heart failure patients at Mercy Hospital Washington has been a major success, according to the doctor ...

Before starting an IV drip, a healthcare professional will assess the patient’s condition and determine the type of solution ...

Nuwellis (NASDAQ:NUWE – Get Free Report) is set to announce its earnings results before the market opens on Monday, November ...

Q3 2024 Earnings Call Transcript November 11, 2024 9:00 AM ETCompany ParticipantsVivian Cervantes - IRNestor Jaramillo ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

Water and sodium retention during severe hypothyroidism create a state of volume depletion, low extracellular fluid osmolality ... [40] Furthermore, oral sodium overload in hypothyroid subjects ...

Oct. 30, 2024 — New research suggests older adults wait 3-6 months after a heart attack before elective noncardiac surgery to reduce the risk of serious complications like stroke or another heart ...